Resmed reports 37% jump in FY25 net income, tops estimates
Make us a preferred source
Make us a preferred source on Google
The news: Respiratory health company ResMed reported a 37% jump in full-year net income to USD1.40 billion ($2.18 billion), edging out Visible Alpha forecasts of USD1.37 billion, as chairman and CEO Mick Farrell cited "robust global demand" for its sleep and breathing health devices during the period. The result is up from net income of USD1.02 billion in fiscal 2024.
The numbers: Dual-listed ResMed, Australia's largest manufacturer and exporter of medical devices, declared a quarterly dividend of 60 US cents per share, up 13% from 53 US cents in the prior corresponding period, and above consensus estimates of 59 US cents per share.
The San Diego-based company reported a 10% uptick in annual revenue to USD5.15 billion, while gross margin improved 270 basis points to 59.4%.
The context: Farrell said the strong finish to the year reflected ongoing momentum across the business, driven by robust global demand for the company's sleep and breathing health devices, as well as its expanding digital health ecosystem.
What they said: "As we move into fiscal year 2026, we will continue to invest in innovation, scale our digital health capabilities, and partner with patients, providers, payers, and policymakers to ensure more people around the world have access to the care they need to sleep better, breathe better, and live longer and healthier lives," Farrell said.
The source: ASX
